Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

AIM: To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS: This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Gastrointest Oncol
Hlavní autoři: Chung, Moon Jae, Kang, Huapyong, Kim, Ho Gak, Hyun, Jong Jin, Lee, Jun Kyu, Lee, Kwang Hyuck, Noh, Myung Hwan, Kang, Dae Hwan, Lee, Sang Hyub, Bang, Seungmin
Médium: Artigo
Jazyk:Inglês
Vydáno: Baishideng Publishing Group Inc 2018
Témata:
Clinical Trials Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6304301/
https://ncbi.nlm.nih.gov/pubmed/30595804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v10.i12.505
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky